TNFRSF17 and Miyoshi myopathy: In a recently published meta-analysis, 130 MM patients treated with GPRC5D-targeted CAR T-cell therapy demonstrated an ORR of 87%, with 74% of these patients having received prior BCMA-targeted therapy.